Sign in or create an account to add this stock to your watchlist.
About Endocyte (NASDAQ:ECYT)
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ECYT
CUSIP29269A10
Phone765-463-7175
Debt
Debt-to-Equity RatioN/A
Current Ratio37.86
Quick Ratio37.86
Price-To-Earnings
Trailing P/E Ratio-14.01
Forward P/E Ratio-18.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$70,000.00
Price / Sales13,909.93
Cash FlowN/A
Price / CashN/A
Book Value$2.47 per share
Price / Book5.67
Profitability
EPS (Most Recent Fiscal Year)($1.00)
Net Income$-55,060,000.00
Net Margins-70,510.81%
Return on Equity-34.20%
Return on Assets-32.76%
Miscellaneous
Employees44
Outstanding Shares69,500,000
Endocyte (NASDAQ:ECYT) Frequently Asked Questions
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
How were Endocyte's earnings last quarter?
Endocyte (NASDAQ:ECYT) posted its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.03. The biopharmaceutical company earned $0.02 million during the quarter. Endocyte had a negative net margin of 70,510.81% and a negative return on equity of 34.20%. View Endocyte's Earnings History.
What price target have analysts set for ECYT?
4 brokers have issued 12-month target prices for Endocyte's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endocyte's share price to reach $7.00 in the next year. View Analyst Ratings for Endocyte.
Who are some of Endocyte's key competitors?
Some companies that are related to Endocyte include Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Tesaro (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY) and Global Blood Therapeutics (GBT).
Who are Endocyte's key executives?
Endocyte's management team includes the folowing people:
- Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
- Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70)
- Ms. Katherine K. Parker, VP of HR (Age 53)
- Dr. Alison A. Armour, Chief Medical Officer (Age 54)
- Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52)
Has Endocyte been receiving favorable news coverage?
Press coverage about ECYT stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endocyte earned a coverage optimism score of 0.09 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Endocyte's major shareholders?
Endocyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include venBio Select Advisor LLC (8.19%), VHCP Management II LLC (6.19%), BlackRock Inc. (2.48%), Rock Springs Capital Management LP (0.97%), Eventide Asset Management LLC (0.50%) and Millennium Management LLC (0.27%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.
Which institutional investors are selling Endocyte stock?
ECYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Barclays PLC. Company insiders that have sold Endocyte company stock in the last year include Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.
Which institutional investors are buying Endocyte stock?
ECYT stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, VHCP Management II LLC, Rock Springs Capital Management LP, BlackRock Inc., Eventide Asset Management LLC, Tibra Equities Europe Ltd, Baird Financial Group Inc. and Element Capital Management LLC. View Insider Buying and Selling for Endocyte.
How do I buy shares of Endocyte?
Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endocyte's stock price today?
One share of ECYT stock can currently be purchased for approximately $14.01.
How big of a company is Endocyte?
Endocyte has a market capitalization of $1.00 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.
How can I contact Endocyte?
Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.
MarketBeat Community Rating for Endocyte (ECYT)
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Endocyte (NASDAQ:ECYT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Endocyte in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible downside of 50.04%. The high price target for ECYT is $7.00 and the low price target for ECYT is $7.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $7.00 | $7.00 | $7.00 |
| Price Target Upside: | 50.04% downside | 26.70% downside | 92.84% upside | 92.84% upside |
Endocyte (NASDAQ:ECYT) Consensus Price Target History
Endocyte (NASDAQ:ECYT) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Endocyte (NASDAQ:ECYT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Endocyte (NASDAQ ECYT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.86%
Institutional Ownership Percentage: 64.51%
Endocyte (NASDAQ ECYT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Christopher P Leamon | VP | Sell | 5,036 | $9.07 | $45,676.52 | 143,470 |  |
| 12/28/2017 | Philip S Low | Insider | Sell | 50,511 | $4.41 | $222,753.51 | | |
| 12/28/2017 | Philip S Low | Insider | Sell | 50,511 | $4.41 | $222,753.51 | 354,050 | |
| 12/1/2017 | Christopher P Leamon | VP | Sell | 23,231 | $5.04 | $117,084.24 | 150,579 | |
| 11/13/2017 | Philip S Low | Insider | Buy | 5,600 | $4.84 | $27,104.00 | 283,005 | |
| 12/30/2016 | Christopher P. Leamon | VP | Sell | 23,244 | $2.55 | $59,272.20 | | |
| 5/10/2016 | Philip S Low | Insider | Buy | 11,375 | $3.52 | $40,040.00 | 206,606 | |
| 1/19/2016 | Fred A. Middleton | Director | Buy | 10,000 | $2.79 | $27,900.00 | 200,999 | |
| 1/15/2016 | Fred A. Middleton | Director | Buy | 20,000 | $2.80 | $56,000.00 | 200,999 | |
| 4/9/2014 | Allen Ritter | VP | Sell | 1,000 | $21.16 | $21,160.00 | 34,282 | |
| 3/21/2014 | Allen Ritter | VP | Sell | 8,000 | $33.11 | $264,880.00 | 12,722 | |
| 2/14/2014 | Philip Low | Insider | Sell | 6,000 | $15.00 | $90,000.00 | 200,819 | |
| 12/2/2013 | P Ron Ellis | CEO | Sell | 3,000 | $12.00 | $36,000.00 | 29,154 | |
| 9/16/2013 | Allen Ritter | VP | Sell | 2,000 | $17.06 | $34,120.00 | 15,722 | |
| 9/12/2013 | David Meek | Insider | Sell | 10,000 | $15.50 | $155,000.00 | | |
| 9/3/2013 | P Ron Ellis | CEO | Sell | 3,000 | $14.54 | $43,620.00 | 29,154 | |
| 8/30/2013 | Allen Ritter | VP | Sell | 6,000 | $14.36 | $86,160.00 | 17,722 | |
| 8/6/2013 | Chandra Lovejoy | VP | Sell | 7,000 | $17.29 | $121,030.00 | | |
| 8/1/2013 | P Ron Ellis | CEO | Sell | 3,000 | $18.12 | $54,360.00 | 29,154 | |
| 7/15/2013 | P Ron Ellis | CEO | Sell | 3,000 | $17.01 | $51,030.00 | | |
| 5/28/2013 | Ann Hanham | Director | Sell | 9,900 | $14.10 | $139,590.00 | | |
| 5/22/2013 | Ann Hanham | Director | Sell | 40,000 | $14.38 | $575,200.00 | | |
| 5/17/2013 | Ann Hanham | Director | Sell | 37,200 | $14.41 | $536,052.00 | | |
| 5/17/2013 | Binh Nguyen | VP | Sell | 17,300 | $14.42 | $249,466.00 | | |
| 5/15/2013 | Ann Hanham | Director | Sell | 40,200 | $14.69 | $590,538.00 | | |
| 5/14/2013 | Christopher P Leamon | VP | Sell | 5,000 | $14.70 | $73,500.00 | | |
| 2/25/2013 | Chandra D Lovejoy | VP | Sell | 2,102 | $9.70 | $20,389.40 | | |
| 12/26/2012 | Chandra D Lovejoy | VP | Sell | 2,209 | $9.05 | $19,991.45 | | |
| 11/26/2012 | Chandra D Lovejoy | VP | Sell | 2,209 | $8.72 | $19,262.48 | | |
(Data available from 1/1/2013 forward)
Endocyte (NASDAQ ECYT) News Headlines
| Source: |
|
Endocyte (NASDAQ:ECYT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Endocyte (NASDAQ:ECYT) Income Statement, Balance Sheet and Cash Flow Statement
Endocyte (NASDAQ ECYT) Stock Chart for Thursday, May, 24, 2018
Loading chart…
